A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...
Health and Me on MSN13h
Taking a GLP-1 Medication? Here Are Tips To Avoid Regaining Weight This Holiday SeasonWhether you are someone who has lost weight recently or is just someone who is worried about gaining weight during the ...
In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth ...
1don MSN
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...
GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...
VC firm Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with ...
Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led ...
Drug manufacturers are racing to develop an oral version of popular weight loss injectables like Ozempic, and early studies ...
As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...
Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...
The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback